Antiarrhythmic Drugs

Electrophysiological Disorders of the Heart

Volumn , Issue , 2005, Pages 705-729

  Singh, Bramah N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20544442236     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06570-5.50043-5     Document Type: Chapter

References (139)

1. The Cardiac Arrhythmia Suppression Trial II Investigators: (1989) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 227-233. 406–412
2. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: An international consensus on science. 6. Advanced cardiovascular life support. 5. Pharmacology 1: Agents for arrhythmias. Circulation 102(Suppl 1), 1-32. 1–128
3. BN Singh and EM Vaughan Williams (1970) A third class of anti-arrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39 675-687.
4. BN Singh and V. Williams Vaughan (1970) The effect of amiodarone, a new antianginal drug, cardiac muscle. Brit J Pharmacol 39 657-667.
5. Singh BN: Pharmacological Actions of Certain Cardiac Drugs and Hormones: Focus on Antiarrhythmic Mechanisms. D. Phil. Thesis, 1971; Hertford College & University of Oxford. UK. Published also by Futura, Mt. Kisco, NY, 1991, pp 1–98.
6. EM Vaughan Williams (1970) Classification of antiarrhythmic drugs. E. Sandoe, E Flenstedt-Johnson, KH Olesen (Eds) Symposium on Cardiac Arrhythmias AB Astra, Sodertalje: Sweden 440-469.
7. BN Singh and EM Vaughan Williams (1972) A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 6 109-119.
8. BN Singh and O Hauswirth (1974) Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 87 367-382.
9. BN Singh and EM Williams (1971) Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res 29 286-295.
10. S Nattel and BN Singh (1999) Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III actions. Am J Cardiol 84 11-19.
11. BF Hoffman and JT Bigger Jr (1971) Antiarrhythmic drugs. JR DiPalma (Eds) Drill's Pharmacology in Medicine 4th ed. New York: McGraw-Hill 824-852.
12. O Hauswirth and BN Singh (1979) Ionic mechanisms in heart muscle in relationship to the genesis and the pharmacological control of cardiac arrhythmias. Pharmacol Rev 30 5-63.
13. DC Harrison (1985) Is there a rational basis for the modified classification of antiarrhythmic drugs? J Morganroth, EN Moore (Eds) Cardiac Arrhythmias: New Therapeutic Drugs and Devices Boston: Martinus Nijhoff 36-48.
14. TJ Campbell (1983) Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 17 344-352.
15. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. (1991) The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 84-1851. 1831
16. BN Singh (1996) The coming of age of class III antiarrhythmic principle: Retrospective and future trends. Am J Cardiol 78(Suppl 4a), 17-27.
17. R Lazzara (1996) From first class to third class: Recent upheaval in antiarrhythmic therapy—lessons from clinical trials. Am J Cardiol 78 28-33.
18. BN Singh (1995) Expanding indications for the use of class III antiar-rhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 6 887-900.
19. LM Hondeghem and DJ Snyders (1990) Class III anti-arrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation 81 686.
20. AJ Camm, R Karam and CM Pratt (1998) The azimilide post-infarct survival evaluation (ALIVE) trial. Am Cardiol 81 35D-339. D
21. E Pritchett, R Page, S Connolly and S Marcello (1998) Azimilide treatment of atrial fibrillation. Circulation 98(17), 1. 633
22. W Sun, JSM Sarma and BN Singh (2002) Chronic and acute effects of dronedarone in the action potential of rabbit atrial muscle preparations: Comparison with amiodarone. J Cardiovasc Pharmacol 39 677-684.
23. Z Wang, LC Pelletier, M Talajic and S Nattel (1990) Effects of flecainide and quinidine on human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit and dog tissues. Circulation 82 274-283.
24. KK Teo, S Yusuf and CD Furberg (1993) Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials. JAMA 270 1589-1595.
25. SE Coplen, EM Antman and JA Berlin (1990) Efficacy and safety of quini-dine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 82 1106-1116.
26. MM Kirk and MR Gold (2000) Disopyramide phosphate. Card Electrophysiol Rev 4 269-271.
27. S MacMahon, R Collins, R Perot, et al. (1988) Effects of prophylactic lidocaine in suspected acute myocardial infarction: An overview of results from randomized, controlled trials. JAMA 260 1910-1916.
28. Impact Research Group: (1984) International mexiletine and placebo antiarrhythmic coronary trial: Report on arrhythmias and other findings. J Am Coll Cardiol 4 1148-1156.
29. DS Ho, RP Zecchin, DA Richards, et al. (1994) Double-blind trial of ligno-caine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 344 18-23.
30. BN Singh (1992) Routine prophylactic lidocaine administration in acute myocardial infarction: An idea whose time is all but gone? Circulation 86 1033-1035.
31. R Ruffy (2000) Flecainide—2000 Update. Card Electrophysiol Rev 4 277-279.
32. M Valderrabano and BN Singh (1999) Electrophysiologic and antiarrhythmic effects of propafenone: Focus on atrial fibrillation. J Cardiovasc Pharmacol Ther 4 183-198.
33. PJ Schwartz, MT La Rovere and E Vanoli (1992) Autonomic nervous system and sudden cardiac death: Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 85(1 Suppl), I77-187.
34. IT Meredith, A Broughton, GL Jennings and MD Esler (1991) Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325 618-624.
35. MJ Reiter and JA Reiffel (1998) Importance of beta-blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82 91-105.
36. MJ Reiter (2000) Antiarrhythmic impact of anti-ischemic, antifailure and other cardiovascular strategies. Cardiac Electrophysiol Rev 194-205.
37. BN Singh (1999) Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 10 283-301.
38. BN Singh and JSM Sarma (2000) Beta-blockers and calcium-channel blockers as antiarrhythmic drugs. DP Zipes, J Jalife (Eds) Cardiac Electrophysiology. From Cell to the Bedside Philadelphia: WB Saunders 903-921.
39. PJ Schwartz (1985) The idiopathic long QT interval syndrome: Progress and questions. Am Heart J 109 399-405.
40. HL Tan, CJ Hou, MR Lauer and RJ Sung (1995) Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Int Med 122(9), 701-714.
41. AC Wiesfeld, HJ Crijns, YS Tuininga and KI Lie (1996) Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Pacing Clin Electrophysiol 19 1026-1035.
42. G Steinbeck, D Andersen, P Bach, et al. (1992) A comparison of electro-physiologically guided antiarrhythmic drug therapy with beta-blocker therapy to patients with symptomatic sustained tachyarrhythmias. N Engl J Med 327 987-993.
43. AP Hallstrom, LA Cobb, BH Yu, et al. (1991) An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 68 1025-1031.
44. S Yusuf, J Wittes and L Friedman (1988) Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260 2088-2093.
45. Norwegian Multicenter Study Group: (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocar-dial infarction. N Engl J Med 304 801-807.
46. Beta-blocker Heart Attack Trial Research Group: (1982) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247 1707-1714.
47. MJ Kendall, KP Lynch, A Hjalmarson and J Kjekshus (1995) Beta-blockers and sudden cardiac death. Ann Int Med 123 358-367.
48. A Hjalmarson (1997) Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80(9B), 35J-39J.
49. SS Gottlieb, RJ McCarter and RA Vogel (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 489-495.
50. DG Julian, AJ Camm, G Franglin, et al. (1997) For the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349 667-673.
51. JA Cairns, SJ Connolly, RJ Roberts and M Gent (1997) For the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 394 675-682.
52. F Boutitie, JP Boissel, SJ Connolly, et al. (1999) and the EMIAT and CAMIAT Investigators. Amiodarone interaction with β-blockers: Analysis of the merged EMIAT and CAMIAT databases. Circulation 99 2268-2275.
53. JR Teerlink and BM Bassie (1999) Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 8 94R-102R.
54. K Chadda, S Goldstein, R Byington and JD Curb (1986) Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73 503-513.
55. MERIT-HEFT Study Group: (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart Failure (MERIT-HF). Lancet 353 2001-2007.
56. CIBIS II Investigators and Committees: (1999) The cardiac insufficiency bisoprolol study CIBIS II. Lancet 353 9-13.
57. M Packer, M. Bristow Mr, JN Cohn, et al. (1996) For the US Carvedilol Heart Failure Study group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 1349-1355. 1360
58. M Packer, F. Coats Fowler, et al. (2001) The Carvedilol, Prospective Randomized Cumulative Survival Study Group. N Engl J Med 344 1651-1658.
59. The Best Steering Committee Design of the Beta Blocker Evaluation Trial (BEST). Am J Cardiol 75 75I-132. 122
60. BN Singh (1996) The coming of age of the class III antiarrhythmic principle: Retrospective and future trends. Am J Cardiol 78(Suppl 4A), 17-27.
61. BN Singh (1998) Antiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 81(6A), 3D-13D.
62. I Kodama, K Kamiya and J Toyama (1997) Cellular electropharmacology of amiodarone. Cardiovasc Res 35 13-29.
63. BN Singh (1995) Expanding indications for the use of class III antiar-rhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 6 887-900.
64. BN Singh (1992) Antiarrhythmic action of dl-sotalol in ventricular and supraventricular arrhythmias. J Cardiovasc Pharmacol 2 590.
65. BN Singh (1999) Sotalol: Current status and expanding indications. J Cardiovasc Pharmacol Ther 4 59-65.
66. The CASCADE Investigators. (1993) The Cascade Study-Randomized Anti-Arrhythmic Drug Therapy in Survivors of Cardiac Arrest in Seattle. Am J Cardiol 72 280-287.
67. JW Mason (1993) and the ERVEM Investigators: A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. N Engl J Med 329 445-451.
68. BN Singh and R Ahmed (1994) Class III antiarrhythmic drugs. Curr Opin Cardiol 9 12-22.
69. C Torp-Pedersen, M Moller, PE Bloch-Thomsen, et al. (1999) For the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341 857-865.
70. KT Murray (1998) Ibutilide. Circulation 97 493-497.
71. S Nattel, L Liu and D St George (1998) Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 37 627-635.
72. MM Scheinman, JH Levine, DS Cannom, et al. (1995) Intravenous Amiodarone Multicenter Investigative Group: Dose ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 92 326.
73. PR Kowey, JH Levine, JM Herre, et al. (1995) Intravenous Amiodarone Multicenter Investigative Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 92 3255-3263.
74. PJ Kudenchuk, LA Cobb, MK Copass, et al. (1999) Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341 871.
75. P Dorian, D Cass, Schwartz, et al. (2002) Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346 884-890.
76. BN Singh (2000) Initial antiarrhythmic drug therapy during resuscitation from sudden cardiac death: A time for a fundamental change in strategy? J Cardiovasc Pharmacol Ther 5 3-9.
77. BN Singh (2001) What niche will newer class III antiarrhythmic drugs occupy? Curr Cardiol Rep 3 314-323.
78. BN Singh (1996) Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol 78 41-53.
79. JG Papp, M Nemeth, I Krassoi, et al. (1996) Differential electro-physiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Ther 1 187-196.
80. S Sicouri, S Moro, S Litovsky, et al. (1997) Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 8 1269-1279.
81. G Cui, L Sen, PT Sager, et al. (1995) Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol 75 465-469.
82. SH Hohnloser and BN Singh (1995) Proarrhythmia with class III antiar-rhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6 920-936.
83. PT Sager, P Uppal, CT Follmer, et al. (1993) The frequency-dependent electrophysiologic effects of amiodarone in humans. Circ 88 1063-1068.
84. SJ Connolly (1999) Evidence based-analysis of amiodarone efficacy and safety. Circulation 100 2025-2034.
85. N Nasir, US Swarna, KA Boahene, et al. (1996) Therapy of sustained ventricular arrhythmias with amiodarone: Prediction of efficacy with serial electrophysiologic studies. J Cardiovasc Pharmacol Ther 1 123-133.
86. J Skoulargis, C Rothlisberger, D Skudicky, et al. (1993) Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol 72 423-427.
87. SH Chun, PT Sager, WG Stevenson, et al. (1995) Long-term efficacy of amiodarone for the maintenance of sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 76 47-50.
88. SH Hohnloser, T Meinertz, T Dummbacher, et al. (1991) Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: Results of prospective, placebo-controlled study. Am Heart J 121 89-90.
89. Guarnieri T: Intravenous amiodarone reduces CABG hospitalization: The ARCH Trial. Presentation at the NASPE Annual Scientific Meeting, San Diego, May 1998.
90. EG Daoud, AS Strickenberger, C Man, et al. (1997) Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 337 1785-1791.
91. D Roy, M Talajic, P Dorian, et al. (2000) For the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342 913-918.
92. GE Kochiadakis, NE Igoumenidis, ME Marketou, et al. (1998) Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 81 995-1005.
93. BN Singh (1999) A Symposium: Approaches to Controlling Cardiac Arrhythmias: Focus on Amiodarone—the last 15 Years. Am J Cardiol 84(Supp 9A), 1R-174R
94. R Kato, L Yabek, N Ikeda, et al. (1986) Electrophysiologic effects of dextro-and levo-isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 7 116-126.
95. MJ Antonaccio and AW Gomoll (1990) Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol 65 12A-20A.
96. K Nademanee, G Feld, JA Hendrickson, et al. (1985) Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 72 555-564.
97. DG Benditt, JH Williams, J Jin, et al. (1999) For the dl-Sotalol Atrial Fibrillation/Flutter Study Group. Maintenance of sinus rhythm with oral dl-sotalol therapy in patients with symptomatic atrial fibrillation and flutter: A dose-response study. Am J Cardiol 84 270-277.
98. A Pacifico, S Hohnloser, JH Williams, et al. (1999) For the dl-sotalol implantable cardioverter-defibrillator study group. N Engl J Med 340 1855-1862.
99. C Movsowitz and FE Marchlinski (1998) Interactions between implantable cardioverter-defibrillators and class III antiarrhythmic drugs. Am J Cardiol 82 411.
100. BN Singh, P Deedwania, K Nademanee, et al. (1987) Sotalol: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 34 311-330.
101. SC Reimold, CO Cantillon, PL Priedman, et al. (1993) Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 71 558.
102. S Juul-Moller, N Edvardsson and NR Ahlberg (1990) Sotalol versus quini-dine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 82 1932.
103. MJ Suttorp, JH Kignma and HOJ Peels (1991) Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 68 1163.
104. BN Singh, B Lopez and JSM Sarma (1998) Significance and prevention of atrial fibrillation occurring after surgery: A time for fundamental change in strategy? J Cardiovasc Pharmacol Therapeut 3 259.
105. R Kehoe, T Zheutlin, C Dunnington, et al. (1990) Safety and efficacy of sotalol in patients with drug refractory sustained ventricular tachyarrhythmias. Am J Cardiol 65 58A.
106. RE Haynes, RL Chinn, MK Copass, et al. (1981) Comparison of bretylium tosylate and lidocaine in management of out-of-hospital ventricular fibrillation: A randomized clinical trial. Am J Cardiol 48 353.
107. DW Olson, BM Thompson, JC Darin, et al. (1984) A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann Emerg Med 13 807-811.
108. KS Lee and JK Gibson (1995) Unique ionic mechanism of action of ibutilide on freshly isolated heart cells. Circulation 92 2755-2757.
109. KA Ellenbogen, BS Sambler, MA Wood, et al. (1996) Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: A dose-response study. J Am Coll Cardiol 28 130-136.
110. BS Stambler, MA Wood, KA Ellenbogen, et al. (1996) Efficacy of safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94 1613-1621.
111. KA Ellenbogen, HF Clemo, BS Stambler, et al. (1996) Efficacy of ibutilide termination of atrial fibrillation and flutter. Am J Cardiol 78 42-45.
112. H Oral, HJ Souza, GF Michaud, et al. (1999) Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide treatment. N Engl J Med 340 1849-1854.
113. GV Nacarelli, KS Lee, JK Gibson, et al. (1996) Electrophysiology and pharmacology of ibutilide. Am J Cardiol 78 12-16.
114. BN Singh (1997) Acute conversion of atrial flutter and fibrillation: Direct current cardioversion versus intravenously administered pure class III agents. J Amer Coll Cardiol 29 391-393.
115. DM Roden (1996) Ibutilide and the treatment of atrial arrhythmias. A new drug—almost unheralded—is now available to US physicians. Circulation 94 1499-1502.
116. BS Stambler (2000) Update on intravenous ibutilide. Cardiac Electrophysiol Rev 4 243-247.
117. Glatter KA, Chatterjee K, Huang S, et al: Is it safe to use intravenous ibutilide in patients receiving chronic amiodarone therapy? Circulation 198; 98:4417.
118. PR Kowey, JT Vanderlugt and JR Luderer (1996) Safety and risk/benefit analysis of ibutilide for acute conversion of atrial flutter and fibrillation. Am J Cardiol 78 46-52.
119. RH Falk, A Pollak, SN Singh and T Friedrich (1997) Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 29 385-390.
120. E Carmeliet (1992) Voltage- and time-dependent block of the delayed rectifier K + current in cardiac myocytes by dofetilide. J Pharmacol Ther 262 809-815.
121. Data on file in Pfizer database, New York, New York, 2001.
122. SN Singh, RG Zoble, L Yellen, et al. (2000) For the Dofetilide Atrial Fibrillation Investigators. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter. The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 102 2383-2390.
123. S Doshi and BN Singh (2000) Pure class III antiarrhythmic drugs: Focus on dofetilide. J Cardiovasc Pharmacol Ther 5 237-247.
124. R Farshi, D Kistner, JS Sarma, et al. (1999) Ventricular rate control in chronic atrial fibrillation during daily and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 33 304-310.
125. RG Tieleman, IC Van Gelder, HJ Crijn, et al. (1998) Early recurrences of atrial fibrillation after electrical conversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 31 167-173.
126. DG Wyse (2000) Calcium channel blockers. Cardiac Electrophysiol Rev 4 308-311.
127. SH Lee, SA Chen, CT Tai, et al. (1996) Electropharmacologic characteristics and radiofreqency catheter ablation of sustained ventricular tachycardia in patients without structural heart disease. Cardiology 87 33-41.
128. SL Wilbur and FE Marchlinski (1997) Adenosine as an antiarrhythmic agent. Am J Cardiol (12A), 30-37.
129. JB Conti, LC Belardinelli and AB Curtis (1995) Usefulness of adenosine in the diagnosis of tachyarrhythmias. Am J Cardiol 75 952-955.
130. TW Smith (1988) Digitalis: Mechanisms of action and clinical use. N Engl J Med 318 358-365.
131. B Fermini, NK Jurkiewicz and B Jow (1995) Use dependent effect of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization block or delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26 259-267.
132. JJ Salata and RR Brooks (1997) Pharmacology of azimilide dihydrochlo-ride (NE-10064), a class III antiarrhythmic agent. Cardiovas Drug Rev 15 137-156.
133. SC Black, JL Butterfield and BR Lucchesi (1993) Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 22 810-818.
134. M Restivo, M Hegazy and M El-Hamamy (1996) Antiarrhythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model. PACE 19 664.
135. E Guillemare, A Martion, D Nisato, et al. (1999) Acute effects of dronedarone and amiodarone on IK1, I Kr, and IKs in guinea pig ventricular myocytes. Fund Clin Pharmacol 13 389-395.
136. BN Singh and JSM Sarma (2001) Mechnaims of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Ther 6 69-87.
137. AE Corey, H Al-Khalidi, C Brezovic, et al. (1997) Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Clin Pharmacol Ther 61 205-212.
138. E Pritchett, P Page, S Connelly, et al. (1999) Azimilide treatment in atrial fibrillation. Circulation 98(Suppl), 1633(Abstract)
139. W Sun, JSM Sarma and BN Singh (1999) Electrophysiologic effects of dronedarone (SR33589), on non-diodinate benzfuran derivative, in the rabbit heart: Comparison with amiodarone. Circulation 100 2276-2283.